tiprankstipranks
Trending News
More News >

Amgen down 5% after reporting data from Phase 2 study of MariTide

Share of Amgen (AMGN) are down $14.58, or 5%, to $274.75 in afternoon trading after the company announced full results from Part 1 of the Phase 2 study of MariTide, a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide demonstrated up to about 20% average weight loss in people living with obesity without Type 2 diabetes compared with 2.6% in the placebo arm, and up to about 17% average weight loss in people living with obesity with T2D, compared with 1.4% in the placebo arm, per the efficacy estimand, the company reported.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1